000			02179 a2200553 4500
005			20250517123912.0
264		0	_c20180330
008			201803s 0 0 eng d
022			_a1091-6490
024	7		_a10.1073/pnas.1610456113 _2doi
040			_aNLM _beng _cNLM
100	1		_aOkimoto, Ross A
245	0	0	_aPreclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. _h[electronic resource]
260			_bProceedings of the National Academy of Sciences of the United States of America _c11 2016
300			_a13456-13461 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aCell Line, Tumor
650	0	4	_aDrug Resistance, Neoplasm _xdrug effects
650	0	4	_aEnzyme Activation _xdrug effects
650	0	4	_aFemale
650	0	4	_aGene Knockdown Techniques
650	0	4	_aHeterocyclic Compounds, 2-Ring _xadverse effects
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMAP Kinase Signaling System _xdrug effects
650	0	4	_aMechanistic Target of Rapamycin Complex 1 _xmetabolism
650	0	4	_aMice, SCID
650	0	4	_aMutation _xgenetics
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProto-Oncogene Mas
650	0	4	_aProto-Oncogene Proteins B-raf _xantagonists & inhibitors
650	0	4	_aSulfonamides _xadverse effects
650	0	4	_aTreatment Outcome
700	1		_aLin, Luping
700	1		_aOlivas, Victor
700	1		_aChan, Elton
700	1		_aMarkegard, Evan
700	1		_aRymar, Andrey
700	1		_aNeel, Dana
700	1		_aChen, Xiao
700	1		_aHemmati, Golzar
700	1		_aBollag, Gideon
700	1		_aBivona, Trever G
773	0		_tProceedings of the National Academy of Sciences of the United States of America _gvol. 113 _gno. 47 _gp. 13456-13461
856	4	0	_uhttps://doi.org/10.1073/pnas.1610456113 _zAvailable from publisher's website
999			_c26595368 _d26595368